Regal Investment Advisors Has Upped Consolidated Edison (ED) Holding by $477,624; Arrowpoint Asset Management Position in Revance Therapeutics (RVNC) Lowered by $13.96 Million as Share Price Declined

April 25, 2018 - By Henry Gaston

Arrowpoint Asset Management Llc decreased its stake in Revance Therapeutics Inc (RVNC) by 18.67% based on its latest 2017Q4 regulatory filing with the SEC. Arrowpoint Asset Management Llc sold 398,787 shares as the company’s stock declined 12.21% with the market. The institutional investor held 1.74 million shares of the health care company at the end of 2017Q4, valued at $62.09M, down from 2.14 million at the end of the previous reported quarter. Arrowpoint Asset Management Llc who had been investing in Revance Therapeutics Inc for a number of months, seems to be less bullish one the $1.07B market cap company. The stock decreased 1.36% or $0.4 during the last trading session, reaching $29.05. About 24,755 shares traded. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 51.24% since April 25, 2017 and is uptrending. It has outperformed by 39.69% the S&P500.

Regal Investment Advisors Llc increased its stake in Consolidated Edison Inc (ED) by 8.12% based on its latest 2017Q4 regulatory filing with the SEC. Regal Investment Advisors Llc bought 5,686 shares as the company’s stock declined 8.41% with the market. The institutional investor held 75,708 shares of the power generation company at the end of 2017Q4, valued at $6.43M, up from 70,022 at the end of the previous reported quarter. Regal Investment Advisors Llc who had been investing in Consolidated Edison Inc for a number of months, seems to be bullish on the $24.22 billion market cap company. The stock decreased 0.43% or $0.34 during the last trading session, reaching $77.97. About 53,208 shares traded. Consolidated Edison, Inc. (NYSE:ED) has declined 1.18% since April 25, 2017 and is downtrending. It has underperformed by 12.73% the S&P500.

Investors sentiment decreased to 1.06 in Q4 2017. Its down 0.02, from 1.08 in 2017Q3. It fall, as 41 investors sold ED shares while 213 reduced holdings. 63 funds opened positions while 207 raised stakes. 169.29 million shares or 0.15% less from 169.54 million shares in 2017Q3 were reported. Vestor Cap Lc reported 600 shares. Catawba Capital Va holds 0.16% or 8,103 shares in its portfolio. Rare holds 3,648 shares. Moreover, Huntington State Bank has 0.06% invested in Consolidated Edison, Inc. (NYSE:ED). Hamel Assocs holds 1.58% or 39,256 shares in its portfolio. Sg Americas Secs reported 0.06% of its portfolio in Consolidated Edison, Inc. (NYSE:ED). Wealthfront has invested 0.02% in Consolidated Edison, Inc. (NYSE:ED). Cibc Asset Mngmt stated it has 0.02% in Consolidated Edison, Inc. (NYSE:ED). Neuberger Berman Group Inc Limited Liability Co, New York-based fund reported 38,611 shares. Parsons Mngmt Ri accumulated 12,126 shares. Adirondack Rech And Management reported 4,315 shares or 0.14% of all its holdings. Massmutual Trust Fsb Adv invested 0.01% of its portfolio in Consolidated Edison, Inc. (NYSE:ED). Ashfield Capital Prns Ltd Liability Corporation holds 0.12% or 10,555 shares in its portfolio. Hyman Charles D invested in 2,921 shares. Asset Management One Ltd has invested 0.12% of its portfolio in Consolidated Edison, Inc. (NYSE:ED).

Regal Investment Advisors Llc, which manages about $657.66 million and $448.69 million US Long portfolio, decreased its stake in Berkshire Hathaway Inc D (BRKB) by 1,597 shares to 14,839 shares, valued at $2.94M in 2017Q4, according to the filing. It also reduced its holding in First Tr Lrg Cp Vl Alpha (FTA) by 16,531 shares in the quarter, leaving it with 62,103 shares, and cut its stake in Vanguard Index Fds (VTI).

Among 17 analysts covering Con Edison (NYSE:ED), 1 have Buy rating, 6 Sell and 10 Hold. Therefore 6% are positive. Con Edison had 51 analyst reports since July 29, 2015 according to SRatingsIntel. The stock of Consolidated Edison, Inc. (NYSE:ED) earned “Underweight” rating by Morgan Stanley on Thursday, August 10. The rating was downgraded by Jefferies to “Hold” on Tuesday, June 13. Evercore downgraded the shares of ED in report on Tuesday, September 26 to “Underperform” rating. As per Monday, August 10, the company rating was maintained by BMO Capital Markets. Jefferies maintained it with “Hold” rating and $83.5 target in Wednesday, August 30 report. UBS maintained the stock with “Sell” rating in Monday, May 8 report. The stock of Consolidated Edison, Inc. (NYSE:ED) earned “Underperform” rating by Credit Suisse on Wednesday, January 25. The stock of Consolidated Edison, Inc. (NYSE:ED) has “Hold” rating given on Sunday, October 1 by RBC Capital Markets. On Monday, October 19 the stock rating was downgraded by Goldman Sachs to “Sell”. The firm has “Neutral” rating by Mizuho given on Thursday, May 12.

Since December 31, 2017, it had 37 insider purchases, and 1 insider sale for $118,653 activity. McAvoy John had bought 29 shares worth $2,344. $2,306 worth of stock was bought by Sanchez Robert on Wednesday, February 28. On Wednesday, January 31 the insider Nadkarni Gurudatta D bought $2,102. Shukla Saumil P also bought $3,832 worth of Consolidated Edison, Inc. (NYSE:ED) shares. 27 shares were bought by Moore Elizabeth D, worth $2,183 on Wednesday, January 31. $2,344 worth of Consolidated Edison, Inc. (NYSE:ED) shares were bought by Cawley Timothy.

Investors sentiment increased to 2.8 in 2017 Q4. Its up 1.80, from 1 in 2017Q3. It increased, as 6 investors sold RVNC shares while 19 reduced holdings. 31 funds opened positions while 39 raised stakes. 31.34 million shares or 15.17% more from 27.21 million shares in 2017Q3 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) holds 1,193 shares or 0% of its portfolio. Ameritas Inv Ptnrs stated it has 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Moreover, Legal And General Grp Public Ltd Co has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC). Arrowmark Colorado Holding Ltd Llc holds 1.74M shares or 0.63% of its portfolio. Bnp Paribas Arbitrage Sa has 4,849 shares. Winch Advisory Svcs Limited owns 200 shares for 0% of their portfolio. Tower Ltd Liability Corp (Trc) invested in 0% or 46 shares. Victory Capital Incorporated stated it has 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC). Suffolk Capital Mngmt Ltd Liability owns 23,661 shares or 0.11% of their US portfolio. Essex Management Limited Com stated it has 0.56% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Goldman Sachs Grp Inc Inc stated it has 26,546 shares. First Personal Fincl Services holds 1,132 shares or 0.01% of its portfolio. California-based Wells Fargo And Comm Mn has invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). 1492 Capital Mngmt Limited Liability Co, Wisconsin-based fund reported 38,966 shares. Tiaa Cref Ltd Liability Corporation has invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC).

Arrowpoint Asset Management Llc, which manages about $5.56 billion and $9.88B US Long portfolio, upped its stake in Descartes Sys Group Inc (NASDAQ:DSGX) by 162,272 shares to 2.88M shares, valued at $81.76 million in 2017Q4, according to the filing. It also increased its holding in Healthstream Inc (NASDAQ:HSTM) by 140,295 shares in the quarter, for a total of 532,004 shares, and has risen its stake in Shutterstock Inc (NYSE:SSTK).

Analysts await Revance Therapeutics, Inc. (NASDAQ:RVNC) to report earnings on May, 8. They expect $-0.63 earnings per share, up 32.98% or $0.31 from last year’s $-0.94 per share. After $-1.14 actual earnings per share reported by Revance Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -44.74% EPS growth.

Since March 7, 2018, it had 1 buying transaction, and 6 sales for $2.77 million activity. On Wednesday, March 7 the insider Browne L Daniel sold $857,505. 20,000 shares were sold by SILVERNAIL LAUREN P, worth $640,000 on Wednesday, March 7. $168,045 worth of Revance Therapeutics, Inc. (NASDAQ:RVNC) shares were sold by GARDNER PHYLLIS.

Consolidated Edison, Inc. (NYSE:ED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.